Page last updated: 2024-08-22

platinum and maytansine

platinum has been researched along with maytansine in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	3 (75.00)	24.3611
2020's	1 (25.00)	2.80

Authors

Authors	Studies
Ab, O; Bartle, LM; Coccia, J; Lanieri, L; Lee, J; Pinkas, J; Ponte, JF; Ruiz-Soto, R; Themeles, M; Zhou, Y	1
Birrer, MJ; Konner, JA; Martin, LP; Matulonis, UA; Moore, KN; O'Malley, DM; Ponte, JF; Vergote, I	1
Banerjee, S; Birrer, MJ; Colombo, N; Malek, K; Moore, KN; Oaknin, A; Oza, A; Pautier, P; Vergote, I	1
Park, JY; Park, SG; Seo, MD; Sim, YH; Um, YJ	1

Reviews

1 review(s) available for platinum and maytansine

Article	Year
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future oncology (London, England), 2018, Volume: 14, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Drug Resistance, Neoplasm; Female; Folate Receptor 1; Humans; Immunoconjugates; Maytansine; Ovarian Neoplasms; Platinum	2018

Trials

1 trial(s) available for platinum and maytansine

Article	Year
FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future oncology (London, England), 2018, Volume: 14, Issue:17 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoconjugates; Maytansine; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate	2018

Article

Year

FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer.

Future oncology (London, England), 2018, Volume: 14, Issue:17

Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Immunoconjugates; Maytansine; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Prognosis; Survival Rate

2018

Other Studies

2 other study(ies) available for platinum and maytansine

Article	Year
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia (New York, N.Y.), 2016, Volume: 18, Issue:12 Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Folate Receptor 1; Humans; Immunoconjugates; Maytansine; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Xenograft Model Antitumor Assays	2016
A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models. International journal of molecular sciences, 2022, Oct-15, Volume: 23, Issue:20 Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Immunoconjugates; Immunoglobulin G; Maytansine; Mice; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Xenograft Model Antitumor Assays	2022

Article

Year

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.

Neoplasia (New York, N.Y.), 2016, Volume: 18, Issue:12

Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carboplatin; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Folate Receptor 1; Humans; Immunoconjugates; Maytansine; Mice; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Xenograft Model Antitumor Assays

2016

A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models.

International journal of molecular sciences, 2022, Oct-15, Volume: 23, Issue:20

Topics: Animals; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Female; Heterografts; Humans; Immunoconjugates; Immunoglobulin G; Maytansine; Mice; Ovarian Neoplasms; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Xenograft Model Antitumor Assays

2022